白细胞介素23抑制剂古塞奇尤单抗在银屑病治疗中的应用

Application of the interleukin-23 inhibitor guselkumab in the treatment of psoriasis

古塞奇尤单抗作为首个靶向白细胞介素23的抑制剂, 在多项随机对照临床试验中对中重度银屑病患者的治疗显示出良好的疗效和安全性, 能显著改善患者的生活质量。本文综述白细胞介素23和其抑制剂的作用机制及在银屑病治疗中的应用。

Guselkumab is the first monoclonal antibody that selectively targets interleukin(IL)-23.Several randomized controlled clinical trials have demonstrated that it is highly effective and safe in the treatment of moderate to severe plaque psoriasis,and can significantly improve the quality of life of patients.This review summarizes the action mechanisms of IL-23 and guselkumab,as well as the application of guselkumab in the treatment of psoriasis.